Montelukast as a Treatment of Acute Lung Injury in Sepsis
Yasin Abul¹, Emel Eryuksel², Sait Karakurt³, Turgay Celikel³ and Berrin Ceyhan³ Acute lung injury is a syndrome including acute and persistent lung inflammation with augmented vascular permeability (1). Sepsis is the most common reason for acute lung injury (2,3). The overall mortality rate of acute lung injury has been reported as 25 -58%, although recent advances in the management of sepsis have been revealed (4,5). Many studies have pointed out the role of antiinflammatory treatments of sepsis and sepsis-induced acute lung injury. But anti-inflammatory treatments such as N-acetylcysteine and TNF-alpha blockers have still limited value in the treatment of sepsis-induced lung injury. Sepsis and its effect on lung tissue is a kind of inflammatory storm and it is therefore not easy to control all steps in this inflammatory pathway. On the other hand, the leukotriene receptor antagonist, montelukast, has been shown to ameliorate sepsis induced hepatic and intestinal injury including oxidative stress in rats (6). Montelukast has also been used as an effective agent to decrease fibrosis and oxidative stress in lungs in some animal studies (7, 8) . Acute lung injury due to sepsis is related to some mediators and cytokines, including fibroblastic growth factor and tumor necrosis factor (TNF-alpha), both of which are released in the inflammatory process of acute lung injury and oxidative stress (9,10). Given the multiple lines of evidence that have emerged to support a central role of leukotrienes, we hypothesize that leukotriene receptor antagonist treatment, particularly with montelukast, may reduce the fibrotic phase of acute lung injury due to sepsis. We believe that if our hypothesis is correct, a new perspective will be opened for the medical management of sepsisinduced acute lung injury.
Introduction sepsis is a severe infection complicated by systemic inflammation and extensive tissue injury (11). It has been shown that this tissue injury may cause sequential organ failure activated by inflammatory mediators (12,13). Acute lung injury is one of the most important mortality and morbidity factors in sepsis. Treatment modalities such as starting early intravenous antibiotics, initial fluid resuscitation with a goal directed at the prevention of hypoperfusion, intensive insulin treatment for glucose control, low tidal volume ventilation, or the use of activated protein-C have all been shown to lower the chance of mortality (14) . Since inflammation and inflammatory mediators in sepsis-induced acute lung injury play a crucial role in the pathophysiology of sepsis, anti-inflammatory treatment has become a prominent measure (15) .
What are Montelukast and Leukotrienes?
Leukotrienes are end products of arachidonic acid metabolism and have a role in inflammation by stimulating microvascular permeability and the chemotaxis of leukocytes (16, 17) . Leukotrienes also function in immunologic responses, apoptosis and cellular proliferation. Furthermore, they have been found to increase chemotaxis of fibroblasts (17, 18) . Leukotrienes activate the NADPH oxidase enzyme, causing neutrophilic production of free radicals known to play a role in fibrogenesis (19) . Montelukast is a leukotriene receptor antagonist widely used in the treatment of asthma and allergic rhinitis. Interestingly, a number of recent animal studies have shown that montelukast has an anti-inflammatory effect on some sepsis-induced organ diseases, chiefly of liver and intestine (6). However, montelukast has not been used for the treatment of sepsis-induced lung injury. We theorise that, through the NADPH oxidase pathway or chemotaxis of fibroblasts, montelukast may be used to inhibit inflammatory and fibrotic phase in sepsis-induced acute lung injury. Montelukast may also prevent proliferative effect of leukotrienes on inflammatory cells. In addition, montelukast may decrease chemotaxis of fibroblasts. By way of all these mechanisms, montelukast may be a potential candidate for the treatment of sepsis-induced lung injury. (20, 21) They induce fibroblastic proliferation and myelofibroblastic transformation of fibroblasts in the lung. Some leukotrienes, principally the cys-LT-type, are also known to activate NADPH oxidase causing oxygen-free radical production in neutrophils (22, 23) . These free radicals and leukotriene-induced inflammatory mediators, including fibroblastic growth factor and tumor necrosis factor (TNF-alpha), are co-factors for fibrinogenesis in the lung (24).
Leukotrienes and Fibrosis
However, montelukast has been shown to be an effective agent for decreasing fibrosis in some animal studies, especially in the treatment of fibrosis of interstitial lung diseases (8,24). Similar mechanisms regarding the formation of fibrosis are seen in sepsisinduced lung injury. It is known that there is a fibrotic phase in sepsis-induced lung injury that is pathophysiologically similar to fibrotic phase of interstitial lung disease, suggesting anti-inflamatory treatments used in the treatment of fibrotic lung diseases may also be used for the treatment of fibrosis in Acute lung injury, sepsis, fibrosis and anti-inflammatory treatments Acute lung injury is a feature of acute and unrelenting lung inflammation characterized by amplified vascular permeability (25) . Sepsis is one of the most common reasons for acute lung injury (26) . Acute lung injury due to sepsis is thought to result in a high mortality rate, warranting treatment and preventative measures (27) . If acute lung injury progresses under circumstances such as uncontrolled sepsis and multi-organ failure, it eventually causes diffuse alveolar damage and may finally advance to fibrosis by the proliferation of type-II alveolar cells, myofibroblasts and collagen deposition (28) . Furthermore, the extent and persistence of fibrosis has been reported as a poor prognostic factor in acute lung injury (29, 30) . In animal and human studies, pharmacological agents targeting this inflammatory phase could significantly impact the outcome of acute lung injury. It has been demonstrated that pharmacological agents, such as corticosteroids and neutrophil elastase inhibitors can attenuate lung fibrosis in acute lung injury (28, (31) (32) (33) . But montelukast has not yet been used for the treatment of sepsis-induced lung injury. Montelukast may be also preferred for its low side effect profile, including nausea, dyspepsia, diarrhea, and headaches -temporary and mild side effects that do not cause treatment interruption (34) .
Montelukast therapy may reduce the fibrotic phase of acute lung injury in sepsis
